Literature DB >> 34668980

Pregnancy outcome in women with transfused beta-thalassemia in France.

Emilie Virot1, Isabelle Thuret2, Sabine Jardel3, Raoul Herbrecht4, Florence Lachenal5, François Lionnet6, Marie-José Lucchini7, Julie Machin8, Stanislas Nimubona9, Jean-Antoine Ribeil10, Frederic Galacteros11, Giovanna Cannas3, Arnaud Hot3.   

Abstract

Because of chronic anemia, hypogonadotropic hypogonadism, and iron chelation, pregnancy in homozygous and heterozygous compound beta-thalassemia patients stays a challenge. Pregnancies of transfused beta-thalassemia women registered in the French National Registry, conducted between 1995 and 2015, are described. These pregnancies were compared with pregnancies in healthy women and to data previously published in the literature. Fifty-six pregnancies of 37 women were studied. There were 5 twin pregnancies. Assisted reproductive technologies (ART) were used in 9 pregnancies. Median term at delivery was 39 amenorrhea weeks, and median weight at birth was 2780 g. Cesarean section was performed in 53.6% of the pregnancies. There were 6 thromboembolic events, 6 serious infections, 6 pregnancy-induced hypertensions (PIH), 6 intrauterine growth retardations (IUGR), 5 severe hemorrhages, 4 gestational diabetes, 3 alloimmunizations, 2 heart diseases, and 1 pre-eclampsia. There were 5 infections and 4 osteoporosis in the first year of post-partum. ART and cesarean sections were more often used in the beta-thalassemia group, compared to control subjects. Thromboembolic events, PIH, hemorrhage at delivery, and IUGR were more frequent in the beta-thalassemia group. Time to delivery was not different, but infant weight at birth was significantly smaller in the beta-thalassemia group. In the post-partum period, global maternal complications were more frequent in the beta-thalassemia group. Pregnancy in transfused beta-thalassemia women is safe with rare obstetrical and fetal complications. Cesarean section remains often chosen, and infant weight at birth remains smaller than that in the general population, despite delivery at full term.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Beta-thalassemia; Fetal outcome; Hemoglobinopathy; Iron chelation; Pregnancy; Transfusion

Mesh:

Year:  2021        PMID: 34668980     DOI: 10.1007/s00277-021-04697-4

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  3 in total

1.  Beta-Thalassemia major and pregnancy.

Authors:  F A Gulino; S G Vitale; M Fauzia; S Cianci; C Pafumi; M A Palumbo
Journal:  Bratisl Lek Listy       Date:  2013       Impact factor: 1.278

2.  Pregnancy Outcomes in Women with Homozygous Beta Thalassaemia: A single-centre experience from Oman.

Authors:  Nihal Al-Riyami; Maha Al-Khaduri; Shahina Daar
Journal:  Sultan Qaboos Univ Med J       Date:  2014-07-24

3.  Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.

Authors:  Caterina Borgna-Pignatti; Simone Rugolotto; Piero De Stefano; Huaqing Zhao; Maria Domenica Cappellini; Giovanni Carlo Del Vecchio; Maria Antonietta Romeo; Gian Luca Forni; Maria Rita Gamberini; Roberta Ghilardi; Antonio Piga; Avital Cnaan
Journal:  Haematologica       Date:  2004-10       Impact factor: 9.941

  3 in total
  2 in total

1.  Gestational Diabetes Mellitus in Pregnant Women with Beta-Thalassemia Minor: A Matched Case-Control Study.

Authors:  Veronica Falcone; Florian Heinzl; Bianca Karla Itariu; Theresa Reischer; Stephanie Springer; Dana Anaïs Muin; Petra Pateisky; Philipp Foessleitner; Johannes Ott; Alex Farr; Klara Rosta
Journal:  J Clin Med       Date:  2022-04-06       Impact factor: 4.241

Review 2.  New Entity-Thalassemic Endocrine Disease: Major Beta-Thalassemia and Endocrine Involvement.

Authors:  Mara Carsote; Cristina Vasiliu; Alexandra Ioana Trandafir; Simona Elena Albu; Mihai-Cristian Dumitrascu; Adelina Popa; Claudia Mehedintu; Razvan-Cosmin Petca; Aida Petca; Florica Sandru
Journal:  Diagnostics (Basel)       Date:  2022-08-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.